Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
2nd Annual Forum for Payors -- Advances in Genomics and Personalized Medicine
Evaluate Clinical Utility and Cost-Effectiveness of Molecular Diagnostic Testing
March 24 - 25, 2010 Baltimore , MD
http://www.cbinet.com/show_conference.cfm?confCode=fc10020&field=speakers
Stephen Barnhill, M.D., Chairman and Chief Executive Officer, Health Discovery Corporation
This conference would also be of interest to venture capital, private equity, investment banks, laboratories, attorneys, reimbursement consultants.
Quest Presentation - Barclays
from Yahoo message boards;
11min.--Spent a significant amount of time highlighting the Vermillion test and "other" partnerships.
97% of revenue US based and expect to agressively expand globally.
Will integrate "diagnostic test" results into electronic patient records network.
Emphasized partnerships with innovative smaller companies.
During Q&A: Stated there is significant "acquisition" potential in the industry.
Did not reference HDVY specifically.
Appreciate you keeping us posted on the Quest Webinar today, thanks!
Quest Diagnostics To Speak at the Barclays Capital Global Healthcare Conference
MADISON, N.J., March 16, 2010 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Barclays Capital Global Healthcare Conference in Miami. The presentation is scheduled for Wednesday, March 24, 2010 at 9:00 a.m. Eastern Time.
The presentation will be webcast live during the conference and will be available to registered investors on the following site: http://cc.talkpoint.com/barc002/032310a_rb/?entity=51_L7SKKER and to the public on www.QuestDiagnostics.com/investor. In addition, the archived webcast will be available within 24 hours after the conclusion of the live event and will remain available until April 24, 2010.
September is Prostate Cancer Awareness month
http://pcaawareness.net/pcam_display.html
Could we be hearing news by then?????????
RFE-SVM
"Because RFE-SVM technology was discovered by our scientists, HDC holds the only issued patents in the world for this technology. "
healthdiscoverycorp.com
Worlds First Twitter Prostate Cancer Chat
Twitter’s first Prostate Cancer Survivor Chat will be held on Thursday, July 16 from 4-5:30PM Join the discussion with hashtag #pcachat It will be facilitated by Malecare Prostate Cancer Support. Please follow me @prostatenews or http://www.twitter.com/prostatenews to stay in touch on this new event.
The worlds first twitter cancer survivor support group was held, today, July 9, as a collaboration of Malecare and Out With Cancer. It was actually quite interesting. One participant summed it up by tweeting, “This has been weirdly therapeutic. I feel odd sharing so much, but it feels necessary.”
We know that most of you have heard of Twitter, but may not have an account. Twitter is free, easy to use and, as we have seen with today’s cancer survivor support group, could well be life enhancing for our prostate cancer community. So, please join us! Simply sign up at twitter.com
As always, please feel encouraged to contact me, directly, if you have any questions. darryl@malecare.com
Darryl
Darryl Mitteldorf
http://prostatecancerblog.org/?p=153
Prostate Cancer Petition
http://www.prostatecancerpetition.org/
From Yahoo Message Board:
Breast cancer study:
Pfizer is participating in this study, HDVY has a licensing agreement with them for the use of SVM technology.
Also, Quest is attending a conference on March 24th, the same day that Dr.Barnhill is speaking at the 2nd Annual Forum for Payors. Wouldn't it be something if they made an announcement about the urine test that
Why is Dr. Barnhill speaking at a conference or Forum for insurers unless they have a test available or a test that will soon be available and want to bring it to their attention.
http://www.cbinet.com/show_conference.cf...
Making Partnerships Work in this New Era of U.S. and Global Healthcare Reform
Healthcare reform in the coming years will mean far more than the health insurance reform now being finalized by the Congress and the Obama Administration. It will involve different types and levels of reforms, including FDA, personalized-medicine, medical-home and healthcare-globalization. Embracing and then traversing these new and highly complex landscapes, first successfully and then profitably, will require innovations in science, communications and behavior modification, as well as the creation of new kinds and levels of effective business partnerships.
Understand healthcare reform now and what it will look like three years from now
Learn what key roles reform in the FDA, personalized medicine, medical home and healthcare globalization will play
Understand how to incorporate your partners’ and customers’ perspectives into your sales force effectiveness (SFE) strategies to engage more effectively with them
Define scientific imperatives associated with personalized medicine through a case study review and how policy decisions and evolving partnerships can affect them, both positively and negatively
John A. Norris, JD, MBA, Former Chief Operating Officer, FDA; Chief Operating Officer, Health Discovery Corporation
Stephen Barnhill, M.D., Chairman and Chief Executive Officer, Health Discovery Corporation
June Is Men’s Health Awareness Month
National Men's Health Week was established in 1994 by the Senate and House of Representatives, to show how simple, diagnostic, and screening tests can save lives. This has grown to a month-long educational event. The month of June gives health care providers, public policy makers, the media, and individuals an opportunity to encourage men and boys to seek regular medical advice and early treatment for disease and injury.
Capital Conference Presentation Schedule
The Orange County Hilton Hotel, Irvine/Newport, CA – February 6th, 2010Join us and Sponsor Your Company for the Next Capital Conference at
The John Wayne Hilton, Saturday, April 3rd, 2010
8:15 a.m. Registration and Continental Breakfast and "Presenter's Tables Open"
8:45 a.m. Welcome & Member Recognition
9:00 Health Discovery Corporation – Exposure
Sponsor: Steve Fryer SC Capitol Partners 949-223-0031
9:15 T3 Motion – Exposure
Sponsor: Ray Kau – The Search for Value 949-340-6646
9:30 Galaxy Gaming – Financing / Exposure
Sponsor: Bill Corbett & Charles Volk 415-216-2123
9:45 Java Detour – Funding / Offering
Sponsor: Charles Volk 949-306-3370
10:00 18/8 Fine Men’s Salon – Funding / Offering
Sponsor: Stan Marcus 949-477-8065
10:15 15 minute "Presenter's Display Session"
10:30 InterimLender.Com - Funding
Sponsor: Steve Fryer SC Capitol Partners 949-223-0031
10:45 S&W Seed Company – Funding / IPO
Sponsor: Chet Paulson 503-243-6029
11:00 Global Gateway Media – Exposure
Sponsor: Alex Parsinia 949-306-3370
11:15 Industree Music – Funding / Offering
Sponsor: Jim Stubler 949-306-3370
11:30 30 minute Sponsored Cocktail Reception –
- T3 Motion, 18/8 Fine Men’s Salon, Continental Stock Transfer
12:00 Luncheon
http://www.sciaconference.com/PDF/CapitalConferencePresentationSchedule2-6-10.pdf
AdMeTech Praises Rep. Cummings for Introducing $650 Million Prostate Research Bill
The PRIME Act Follows Historic Congressional Hearing Which Highlighted Lack of Accurate Prostate Diagnostics
WASHINGTON, March 9 /PRNewswire-USNewswire/ -- AdMeTech President and CEO Dr. Faina Shtern and Oscar-winning actor Louis Gossett, Jr. today praised Rep. Elijah Cummings (D-MD) for re-introducing the Prostate Research Imaging and Men's Education (PRIME) Act, which calls for $650 million to improve imaging and blood tests for early detection and treatment of prostate cancer.
Rep. Cummings introduced the legislation last week as a result of his participation in the historic prostate cancer hearing by the House Oversight and Government Reform Committee, which was prompted largely by him and other supporters of the AdMeTech Foundation. Dr. Shtern and Mr. Gossett, Jr. testified at this hearing, as did other key experts of the American Cancer Society, medicine, advocacy groups, National Cancer Institute and the Department of Defense. Mr. Gossett, Jr. was recently diagnosed with early prostate cancer and expressed his commitment to support research, awareness and increased access.
After the hearing, Gossett said, "I am a patient undergoing treatment and a concerned citizen who volunteered to serve in the war against prostate cancer crisis, which disproportionately strikes and kills African American men. It is an honor for me to have partnered with AdMeTech Foundation in having taken part in a historic Congressional hearing. I am grateful to Rep. Cummings for making this hearing possible and for introducing $650 million legislation in support of research and men's education."
Dr. Shtern summarized the expert opinions expressed at the hearing: "In spite of the magnitude of the prostate cancer epidemic, and as reflected in the recent guidelines of the American Cancer Society, men do not have reliable diagnostic tools and consequently, experience a staggering extent of unnecessary biopsies, unnecessary treatment, and patient care failures. Introduction of the PRIME Act is an important step in ending the prostate cancer crisis, which compromises quality of life in millions of men and adds at least $5 billion in health care costs each year." She added. "We commend Rep. Cummings, Committee Chairman Edolphus Towns (D-NY) and Ranking Member Darrell Issa (R-CA) for their outstanding, continuous leadership." Both Rep. Towns and Rep. Issa have previously co-sponsored the PRIME Act, which has found bi-partisan support from 13 other members of U.S. Congress prior to its introduction.
The PRIME Act (H.R. 4756) would invest total $650 million – which represents less than 12 percent of the annual waste in health care costs due to the lack of accurate prostate diagnostics – over the next five years. This includes $500 million for research to develop new imaging technologies for improved early detection and minimally-invasive, patient-tailored treatment; $100 million to develop more specific blood and/or urinary tests for mass screening and prevention; and $50 million for men's education. A companion bill, S. 756, sponsored by Sen. Barbara Boxer (D-CA) and co-sponsored by Sen. John Kerry (D-MA), is pending in the Senate.
PROSTATE CANCER FACTS
Prostate cancer is the most common major cancer in the United States and the second most lethal cancer in men. Prostate cancer kills a man every 19 minutes, even though prostate cancer can be cured when detected early.
Existing prostate diagnostics, such as the PSA biomarker and digital rectal exam, cause widespread underdiagnosis, overdiagnosis and overtreatment. Current diagnostics miss and/or underestimate the extent and/or aggressiveness of prostate cancer and lead to treatment failures in as many as half of all men.
False diagnostic alarms result in a staggering extent of unnecessary biopsies and treatment, costing billions of dollars each year. Up to 88 percent of all biopsies – performed on more than 1 million men blindly and randomly each year at a cost of over $2 billion – do not show prostate cancer.
As many as 54 percent of men with early prostate cancer undergo unnecessary treatment and are left with life-altering complications, such as incontinence and impotence. Improved diagnostic tools, including more specific biomarkers for urinary and/or blood tests which can be used for mass screening and advanced imaging tools to guide biopsies, early detection and treatment, will save lives, enable the least invasive and the most effective patient care, reduce unnecessary procedures, improve quality of life in millions of men and decrease health care costs by at least $5 billion per year.
AdMeTech Foundation is a nonprofit organization with the mission to end the prostate cancer crisis. AdMeTech provides international leadership and conducts ground-breaking programs in research and education to facilitate development of accurate diagnostic tools for early detection and minimally-invasive treatment of prostate cancer. For more information, log onto www.admetech.org
SOURCE AdMeTech Foundation
OVA1 Blood Test Now Available to Aid Pre-surgical Evaluation of Women for Ovarian Cancer
FDA-cleared test helps direct women to the most appropriate surgeon, promoting better outcomes
MADISON, N.J. and FREMONT, Calif., March 9 /PRNewswire-FirstCall/ -- OVA1™, the first blood test cleared by the U.S. Food and Drug Administration (FDA) for aiding in the pre-surgical evaluation of a woman's ovarian mass for cancer, is now available nationally through Quest Diagnostics, Inc. (NYSE:DGX - News), the world's leading cancer diagnostics provider. With the availability of OVA1, physicians can assess, prior to a planned surgery, the likelihood that a woman's ovarian mass is malignant in order to direct her to the most appropriate surgeon, promoting more favorable treatment outcomes. Vermillion, Inc. (OTC:VRML.PK.ob - News), a molecular diagnostics company, developed the test in cooperation with Quest Diagnostics.
OVA1 is the first FDA-cleared protein-based in vitro diagnostic multi-variate index assays (IVDMIA), a new class of state-of-the-art software-based diagnostics. The test combines the results of five well-established protein biomarkers to produce a single numerical result to help a physician classify the likelihood that a woman's mass is cancerous or benign.
"The availability of a new test that can help gynecologists and other physicians determine the likelihood a woman's mass is benign or malignant is a significant development in the battle against this devastating disease," said Karen Orloff Kaplan, MSW, MPH, Sc.D., chief executive officer of the Ovarian Cancer National Alliance, a leading patient advocacy group. "It is a big step towards helping each woman get the most appropriate care for her unique situation."
Ovarian cancer is the leading cause of death from gynecologic cancers in the United States and the fifth-leading cause of cancer deaths in women.(1) Ovarian masses affect an estimated one million women and lead to as many 300,000 ovarian mass surgeries in the United States each year, according to an analysis by third parties on behalf of Quest Diagnostics.
Clinical practice guidelines recommend that women with ovarian cancer be under the care of a gynecologic oncologist. Yet, pre-surgical evaluations of ovarian masses, which include clinical evaluation and radiological tests such as CT scans and ultrasound, may provide inconclusive evidence of cancer. An estimated one third of initial surgeries for ovarian cancer are performed by gynecologic oncologists.(2)
"Studies show that surgery performed by a gynecologic oncologist to remove a cancerous ovarian mass is associated with more favorable outcomes," explained Fred Ueland, M.D., associate professor gynecologic oncology at the University of Kentucky's Markey Cancer Center and principal investigator of the prospective, multi-center OVA1 clinical trial evaluated by the FDA. "Based on my clinical experience, I believe OVA1 will not only help identify more women with ovarian cancer for referral to a gynecologic oncologist and improve cancer treatment outcomes, but it also will give other women greater confidence that their ovarian tumor is benign."
In a prospective clinical study, OVA1, when combined with pre-surgical clinical and radiological assessments and used by non-gynecologic oncologists, detected 92 percent of malignant ovarian masses compared to 72 percent without OVA1. In addition, 14 of 20 woman who participated in the study whose cancer was missed by pre-surgical clinical and radiological assessments would have been identified as having malignant ovarian masses had OVA1 results also been evaluated prior to their surgeries.
"Too often, a gynecologist will operate on a patient for an ovarian mass only to find an invasive malignancy requiring the skill of a specialist to remove," said Jon R. Cohen, M.D., senior vice president and chief medical officer, Quest Diagnostics, and a surgeon. "When this happens, the physician may need to prolong or terminate and reschedule the operation unless a gynecologic oncologist is readily available. OVA1 may help gynecologists and other physicians direct more women with cancer to a gynecologic oncologist for their first and hopefully only surgery."
Approximately 21,600 new cases of ovarian cancer will be diagnosed in the United States in 2009, and approximately 14,600 women will die of the disease.(3)
The FDA announced it had cleared OVA1 in September 2009, and Quest Diagnostics is the only national laboratory services provider to offer it broadly in the United States. For more information, physicians and patients should refer to http://questdiagnostics.com/ or www.QuestDiagnostics.com/womenscancers. Physicians may also refer to http://www.vermillion.com/.
About OVA1
OVA1 is the first protein-based in vitro diagnostic multi-variate index assays (IVDMIA), a new class of state of the art software-based diagnostics, cleared by the FDA. The test utilizes five well-established biomarkers -- Transthyretin (TT or prealbumin), Apolipoprotein A-1 (Apo A-1), Beta2-Microglobulin (Beta2M), Transferrin (Tfr) and Cancer Antigen 125 (CA 125 II) -- and proprietary software to determine the likelihood of malignancy in women with ovarian mass for whom surgery is planned.
OVA1 is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist. It is an aid to further assess the likelihood that malignancy is present when the physician's independent clinical and radiological evaluation does not indicate malignancy. The test should not be used without an independent clinical/radiological evaluation and is not intended to be a screening test or to determine whether a patient should proceed to surgery. Incorrect use of the OVA1 Test carries the risk of unnecessary testing, surgery, and/or delayed diagnosis.
Click on conference brochure on the right it lists all the companies.
Slideshow was about 1:35 minutes.
2010 Milestones:
1- Sign new breast cancer development license
2- Create revenue by commercializing Urine prostate Cancet Test
3- Sign Pancreatic Cancer Test licensing deal
I tried linking the slideshow from the BioMedreports.com again but it didn't work.
Some slides from HDVY's recent presentation to bankers and brokers in Dallas (click icon in the bottom right center of the player to watch full-screen):
http://www.photoshow.com/watch/jD5DW8eQ
2nd Annual Forum for Payors -- Advances in Genomics and Personalized Medicine
Evaluate Clinical Utility and Cost-Effectiveness of Molecular Diagnostic Testing
Mar. 24-25, 2010
8:15 Making Partnerships Work in this New Era of U.S. and Global Healthcare Reform
Healthcare reform in the coming years will mean far more than the health insurance reform now being finalized by the Congress and the Obama Administration. It will involve different types and levels of reforms, including FDA, personalized-medicine, medical-home and healthcare-globalization. Embracing and then traversing these new and highly complex landscapes, first successfully and then profitably, will require innovations in science, communications and behavior modification, as well as the creation of new kinds and levels of effective business partnerships.
Understand healthcare reform now and what it will look like three years from now
Learn what key roles reform in the FDA, personalized medicine, medical home and healthcare globalization will play
Understand how to incorporate your partners’ and customers’ perspectives into your sales force effectiveness (SFE) strategies to engage more effectively with them
Define scientific imperatives associated with personalized medicine through a case study review and how policy decisions and evolving partnerships can affect them, both positively and negatively
John A. Norris, JD, MBA, Former Chief Operating Officer, FDA; Chief Operating Officer, Health Discovery Corporation
Stephen Barnhill, M.D., Chairman and Chief Executive Officer, Health Discovery Corporation
Resistance is at 0.28 and 0.35
Same here! Read it first thing in the morning and ignored it.
Quest Licenses Another Epigenomics Biomarker
February 25, 2009
By a GenomeWeb staff reporter
Type size:
-
+EmailPrinter-friendly versionRSS FeedNEW YORK (GenomeWeb News) — Quest Diagnostics has licensed a biomarker for prostate cancer from Epigenomics, which it plans to use to develop a molecular diagnostic test for diagnosing the disease, Epigenomics said today.
The agreement gives Quest the rights to use the GSTP1 DNA methylation biomarker in order to both develop and market the diagnostic test, which will be performed using patient tissue samples.
Quest licensed the rights to an Epigenomics biomarker for colorectal cancer in 2008 in order to develop a test to help detect that disease.
Financial terms of the agreement were not released.
The clinical lab giant has experience in developing DNA methylation diagnostic tests. It currently offers two such tests, one for Prader-Willi syndrome and one for Angelman syndrome, both of which are neurological epigenetic disorders that may be caused by faulty DNA methylation.
http://www.genomeweb.com/node/912354?emc=el&m=319663&l=1&v=277640021d
I'll drop off the kids and see what else I can find
Exciting day! Thanks to everyone for all the great posts!
Thanks for posting the link!
Cancer Society Stops Urging Docs to offer PSA Test
" The American Cancer Society is urging doctors to make clearer to men that the test used to screen for prostate cancer has limits and may lead to unnecessary treatments that do more harm than good."
http://news.yahoo.com/s/ap/20100303/ap_on_he_me/us_med_prostate_cancer
Just a reminder:
Conference Brochure
MDB CAPITAL GROUP
BRIGHT LIGHTS CONFERENCE
MAY 10-12, 2010
http://mdbcapital.com/assets/files/2010_MDB%20BrightLightConferenceBrochure(1).pdf
Provestus :
Latin for “Most Advanced”, this award is presented to the top 5 companies across all industries with the highest combined Tech Score, Patent Application CAGR and number of patent grants. The PROVECTUS recognizes strength of IP process...The “Best of the Best”.
Conference : Advances in Genomics and Personalized Medicine
March 24-26 Both Barnhill and Norris to speak.
http://www.cbinet.com/show_conference.cf...
Quest Diagnostics to Speak at the RBC Capital Markets 2010 Healthcare Conference
this Wed. March 3 at 9:00am.
http://finance.yahoo.com/news/Quest-Diagnostics-to-Speak-at-prnews-2747594831.html?x=0&.v=1
Forbes: The Mathematics of cancer article
http://www.forbes.com/forbes/2010/0315/opinions-health-cancer-larry-norton-ideas-opinions.html?boxes=Homepagetmagazines
----- Original Message -----
From: <garza@biomedreports.com>
To: "Morgan" >
Sent: Friday, February 19, 2010 9:22 AM
Subject: RE: BioMedReports.Com: hdvy.ob
> Don't let him scare you out of your shares. You don't lose until you sell and it will be well worth your time to hold on to them. Pass it on!
>
>
> -----Original Message-----
> From: "Morgan" <> Sent: Friday, February 19, 2010 7:44am
> To: garza@biomedreports.com
> Subject: BioMedReports.Com: hdvy.ob
>
> This is an enquiry e-mail via http://biomedreports.com/ from:
> Morgan <>
> Mr. Mike Garza,
>
> As much as I dreaded this seems likes Adam Feueurstein covered HDVY in this Biotech stock mailbag article this morning. I am heavily invested in HDVY and am really worried about market reaction to his coverage. Appreciate your advice.
>
> regards,
> Morgan >
Oh no, Adam Feuerstein reviewed HDC in the Biotech Stock Mailbag this morning. I don't know how to link the article. I am heavily invested in HDC but a bit worried to market reaction today.
Biomed report is out!